James Shao

1.9k total citations · 2 hit papers
19 papers, 1.5k citations indexed

About

James Shao is a scholar working on Gastroenterology, Surgery and Hematology. According to data from OpenAlex, James Shao has authored 19 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Gastroenterology, 8 papers in Surgery and 5 papers in Hematology. Recurrent topics in James Shao's work include Gastroesophageal reflux and treatments (6 papers), Gastrointestinal motility and disorders (5 papers) and Helicobacter pylori-related gastroenterology studies (5 papers). James Shao is often cited by papers focused on Gastroesophageal reflux and treatments (6 papers), Gastrointestinal motility and disorders (5 papers) and Helicobacter pylori-related gastroenterology studies (5 papers). James Shao collaborates with scholars based in United States, United Kingdom and Italy. James Shao's co-authors include Mark G. Currie, Steven J. Shiff, Anthony Lembo, Bernard J. Lavins, James E. MacDougall, Caroline B. Kurtz, Xinwei D. Jia, Harvey Schneier, Jeffrey M. Johnston and Linda Lowes and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

James Shao

19 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Longitudinal effect of eteplirsen versus historical control on ambulation in D uchenne muscular dystrophy

2015 372 citations Jerry R. Mendell, Nathalie Goemans et al. Annals of Neurology profile →
Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety

2012 340 citations William D. Chey, Anthony Lembo et al. The American Journal of Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James Shao United States	9	831	622	443	222	209	19	1.5k
Peter Yang United States	17	248 0.3×	259 0.4×	216 0.5×	119 0.5×	103 0.5×	38	1.2k
Rhian Stavely United States	18	203 0.2×	314 0.5×	304 0.7×	149 0.7×	82 0.4×	53	902
Derek Zieker Germany	19	101 0.1×	430 0.7×	391 0.9×	35 0.2×	116 0.6×	45	1.4k
Yanli Zhang China	11	88 0.1×	125 0.2×	63 0.1×	89 0.4×	58 0.3×	39	530
Luting Xu United States	16	66 0.1×	76 0.1×	129 0.3×	64 0.3×	175 0.8×	28	867
Jenna L. Cash United Kingdom	12	35 0.0×	139 0.2×	346 0.8×	37 0.2×	139 0.7×	17	1.1k
C E Bayliss Australia	10	38 0.0×	180 0.3×	144 0.3×	190 0.9×	144 0.7×	13	842
Joelle Romac United States	16	46 0.1×	375 0.6×	303 0.7×	16 0.1×	257 1.2×	24	886
Koji Hosaka United States	19	31 0.0×	75 0.1×	539 1.2×	32 0.1×	263 1.3×	39	1.3k
Bixia Liu China	16	60 0.1×	307 0.5×	391 0.9×	12 0.1×	43 0.2×	36	1.3k

Countries citing papers authored by James Shao

Since Specialization

Citations

This map shows the geographic impact of James Shao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Shao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Shao more than expected).

Fields of papers citing papers by James Shao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Shao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Shao. The network helps show where James Shao may publish in the future.

Co-authorship network of co-authors of James Shao

This figure shows the co-authorship network connecting the top 25 collaborators of James Shao. A scholar is included among the top collaborators of James Shao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Shao. James Shao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Schöffski, Patrick, Michael C. Heinrich, Jonathan C. Trent, et al.. (2024). StrateGIST 1: A first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs).. Journal of Clinical Oncology. 42(16_suppl). 11501–11501. 5 indexed citations

Su, Shengchen, et al.. (2024). P4.11D.05 EGFR Neoantigen Peptide Vaccine Combined with Tislelizumab and Chemotherapy for Advanced NSCLC Resistant to EGFR-TKI Therapy. Journal of Thoracic Oncology. 19(10). S391–S391. 2 indexed citations

Mascarenhas, John, Katarina Luptakova, Jing Wang, et al.. (2021). MPN-336: MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib vs Placebo and Ruxolitinib in JAKi Treatment-Naïve Myelofibrosis Patients. Clinical Lymphoma Myeloma & Leukemia. 21. S363–S363. 4 indexed citations

Vaezi, Michael F., Ronnie Fass, Nimish Vakil, et al.. (2020). IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial. Gastroenterology. 158(8). 2093–2103. 29 indexed citations

Andrae, David, et al.. (2020). Evaluation and Validation of the Modified Reflux Symptom Questionnaire–Electronic Diary in Patients With Persistent Gastroesophageal Reflux Disease. Clinical and Translational Gastroenterology. 11(1). e00117–e00117. 2 indexed citations

Mascarenhas, John, Katarina Luptakova, Jing Wang, et al.. (2020). MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients. Blood. 136(Supplement 1). 43–43. 16 indexed citations

Mascarenhas, John, Marina Kremyanskaya, Ronald Hoffman, et al.. (2019). MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis. Blood. 134(Supplement_1). 670–670. 36 indexed citations

Harrison, Claire, Andrea Patriarca, John Mascarenhas, et al.. (2019). Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients. Blood. 134(Supplement_1). 4164–4164. 22 indexed citations

Shao, James, et al.. (2018). Clinical Response Is Associated with Improvement in Health-Related Quality of Life in Patients with Persistent GERD Symptoms. The American Journal of Gastroenterology. 113(Supplement). S224–S225. 1 indexed citations

10.

Vaezi, Michael F., Ronnie Fass, Nimish Vakil, et al.. (2018). 875 - Iw-3718, a Novel Gastric-Retentive Bile Acid Sequestrant, Improved Heartburn and Regurgitation Symptoms in Patients with Persistent Gerd Despite PPI Treatment: A Double-Blind, Placebo-Controlled Study. Gastroenterology. 154(6). S–174. 5 indexed citations

11.

Mendell, Jerry R., Nathalie Goemans, Louise R. Rodino‐Klapac, et al.. (2016). Eteplirsen, a Phosphorodiamidate Morpholino Oligomer (PMO) for Duchenne Muscular Dystrophy (DMD): Clinical Update and Longitudinal Comparison to External Controls on Six-Minute Walk Test (6MWT) (S28.001). Neurology. 86(16_supplement). 1 indexed citations

12.

Mendell, J., Louise R. Rodino‐Klapac, Zarife Sahenk, et al.. (2016). Eteplirsen, a phosphorodiamidate morpholino oligomer (PMO) for Duchenne muscular dystrophy (DMD): Longitudinal comparison to external controls on six-minute walk test (6MWT) and loss of ambulation (LOA). Neuromuscular Disorders. 26. S154–S154. 2 indexed citations

13.

Mendell, Jerry R., Nathalie Goemans, Linda Lowes, et al.. (2015). Longitudinal effect of eteplirsen versus historical control on ambulation in D uchenne muscular dystrophy. Annals of Neurology. 79(2). 257–271. 372 indexed citations breakdown →

14.

Tack, Jan, et al.. (2014). Evaluation of Daily GI Symptoms in a Phase 2A Study of IW-9179 in Functional Dyspepsia. The American Journal of Gastroenterology. 109. S637–S638. 2 indexed citations

15.

Rao, Satish S.C., Anthony Lembo, Steven J. Shiff, et al.. (2012). A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation. The American Journal of Gastroenterology. 107(11). 1714–1724. 293 indexed citations

16.

Chey, William D., Anthony Lembo, Bernard J. Lavins, et al.. (2012). Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety. The American Journal of Gastroenterology. 107(11). 1702–1712. 340 indexed citations breakdown →

17.

Chang, Lin, Anthony Lembo, Steven J. Shiff, et al.. (2012). Effects of Linaclotide on Abdominal and Bowel Symptoms Over the First Seven Days of Treatment in Patients with Irritable Bowel Syndrome with Constipation. The American Journal of Gastroenterology. 107. S710–S711. 1 indexed citations

18.

Lembo, Anthony, Harvey Schneier, Steven J. Shiff, et al.. (2011). Two Randomized Trials of Linaclotide for Chronic Constipation. New England Journal of Medicine. 365(6). 527–536. 270 indexed citations

19.

Auerbach, Michael, Peter T. Silberstein, R. Timothy Webb, et al.. (2010). Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous Iron in patients with chemotherapy‐induced anemia. American Journal of Hematology. 85(9). 655–663. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact